Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.

ABSTRACT: There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types were significantly altered in patients; those with monoclonal gammopathies showed greater immunosuppression t

SUBMITTER: Tamariz-Amador LE 

PROVIDER: S-EPMC8669666 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature